$SRRK

Gilman Michael sold $137K of SRRK

Gilman Michael sold 2,544 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.54–$54.81, $0.14M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gilman Michael
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include new company fundamentals such as guidance, trial results, contracts, or regulatory actions.

02

Market read

Primarily a sentiment/positioning datapoint for SRRK, with limited expected impact given the 10b5-1 structure.

03

What to watch

The article provides sale size and weighted prices but no context on total holdings, future planned sales, or whether other insiders have concurrent activity.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06 for trades dated 2026-07-01

Background

This is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp, reported as an open-market sale by a director under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Form 4 shows director Gilman Michael sold 2,544 SRRK shares in open-market trades under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal, though it can add slight overhang sentiment if traders focus on insider selling.

Evidence & confidence

The transaction is disclosed via SEC Form 4 and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Traders may overreact to insider sales; 10b5-1 plans are often used to manage liquidity and taxes rather than signal bearish views.

Key entities

  • Scholar Rock Holding Corp

    Subject of the Form 4 insider sale disclosure.

  • Gilman Michael

    Director who sold SRRK shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

$SRRKMed

SRRK Maintained by Evercore ISI Group -- Price Target Raised to

Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.

$SRRKHighAI 9/10

Scholar Rock wins FDA approval for spinal muscle atrophy drug

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.